Equities analysts expect vTv Therapeutics Inc (NASDAQ:VTVT) to announce sales of $1.69 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for vTv Therapeutics’ earnings. The highest sales estimate is $2.50 million and the lowest is $880,000.00. vTv Therapeutics reported sales of $3.38 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The company is scheduled to issue its next earnings results on Thursday, November 14th.
According to Zacks, analysts expect that vTv Therapeutics will report full year sales of $6.16 million for the current fiscal year, with estimates ranging from $4.62 million to $7.70 million. For the next fiscal year, analysts anticipate that the company will report sales of $6.38 million, with estimates ranging from $2.75 million to $10.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. The firm had revenue of $1.83 million for the quarter, compared to analysts’ expectations of $1.63 million.
Several research analysts recently issued reports on VTVT shares. ValuEngine cut shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, June 3rd. Zacks Investment Research cut shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of vTv Therapeutics in a report on Friday, August 16th. Finally, Northland Securities reissued a “buy” rating and set a $8.00 price target on shares of vTv Therapeutics in a report on Thursday, August 1st.
In related news, major shareholder Ronald O. Perelman bought 50,000 shares of the company’s stock in a transaction on Thursday, August 22nd. The stock was bought at an average cost of $1.38 per share, with a total value of $69,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ronald O. Perelman bought 1,212,121 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was bought at an average cost of $1.65 per share, with a total value of $1,999,999.65. The disclosure for this purchase can be found here. Insiders have purchased 3,836,363 shares of company stock valued at $6,265,499 over the last three months. 1.70% of the stock is currently owned by corporate insiders.
A hedge fund recently raised its stake in vTv Therapeutics stock. BlackRock Inc. raised its stake in vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 65,031 shares of the biotechnology company’s stock after buying an additional 13,305 shares during the period. BlackRock Inc. owned approximately 0.12% of vTv Therapeutics worth $93,000 at the end of the most recent reporting period. 3.71% of the stock is currently owned by institutional investors.
NASDAQ VTVT traded down $0.03 during trading hours on Friday, hitting $1.34. 85,592 shares of the stock were exchanged, compared to its average volume of 235,771. The company has a market cap of $75.24 million, a price-to-earnings ratio of -1.94 and a beta of -3.71. vTv Therapeutics has a 12-month low of $0.68 and a 12-month high of $6.09. The stock has a 50-day moving average of $1.37 and a 200 day moving average of $1.67.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Read More: Why do corrections happen?
Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.